| Literature DB >> 30804377 |
Emiliana M Silva1, Jonas N Conde1, Diego Allonso2, Gustavo T Ventura1, Diego R Coelho1, Pedro Henrique Carneiro1, Manuela L Silva3, Marciano V Paes4, Kíssila Rabelo5, Gilberto Weissmuller6, Paulo Mascarello Bisch6, Ronaldo Mohana-Borges7.
Abstract
Dengue is an important mosquito-borne disease and a global public health problem. The disease is caused by dengue virus (DENV), which is a member of the Flaviviridae family and contains a positive single-stranded RNA genome that encodes a single precursor polyprotein that is further cleaved into structural and non-structural proteins. Among these proteins, the non-structural 3 (NS3) protein is very important because it forms a non-covalent complex with the NS2B cofactor, thereby forming the functional viral protease. NS3 also contains a C-terminal ATPase/helicase domain that is essential for RNA replication. Here, we identified 47 NS3-interacting partners using the yeast two-hybrid system. Among those partners, we highlight several proteins involved in host energy metabolism, such as apolipoprotein H, aldolase B, cytochrome C oxidase and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). GAPDH directly binds full-length NS3 and its isolated helicase and protease domains. Moreover, we observed an intense colocalization between the GAPDH and NS3 proteins in DENV2-infected Huh7.5.1 cells, in NS3-transfected BHK-21 cells and in hepatic tissue from a fatal dengue case. Taken together, these results suggest that the human GAPDH-DENV NS3 interaction is involved in hepatic metabolic alterations, which may contribute to the appearance of steatosis in dengue-infected patients. The interaction between GAPDH and full-length NS3 or its helicase domain in vitro as well as in NS3-transfected cells resulted in decreased GAPDH glycolytic activity. Reduced GAPDH glycolytic activity may lead to the accumulation of metabolic intermediates, shifting metabolism to alternative, non-glycolytic pathways. This report is the first to identify the interaction of the DENV2 NS3 protein with the GAPDH protein and to demonstrate that this interaction may play an important role in the molecular mechanism that triggers hepatic alterations.Entities:
Year: 2019 PMID: 30804377 PMCID: PMC6389977 DOI: 10.1038/s41598-019-39157-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The DENV2 NS3 protein interacts with human liver proteins in the yeast two-hybrid system. The yeast strain AH109 was co-transformed with the NS3 bait plasmid, as well as the prey or control plasmids. The growth of the transformant colonies was visualized on double drop-out medium (SD-Leu-Trp; column A). Positive interaction partners were visualized by growth on triple drop-out medium (SD-His-Leu-Trp; column B) and quadruple drop-out medium (SD-Ade-His-Leu-Trp; column C). Strong interactions were indicated by β-galactosidase expression, as evidenced by blue staining on the colony-lift filter assay (column D), indicating HIS3, ADE2 and lacZ reporter gene activation. Transformants containing the plasmids pGBKT7-NS3 and PGADT7-AD (C1), pGBKT7-NS3 and PGADT7-T (SV40 large T-antigen fused to the GAL4 activation domain) (C2), empty pGBKT7 and PGADT7-AD (C3), empty pGBKT7 and PGADT7-T (C4), and pGBKT7-Lam (laminin C) and PGADT7-AD (C5) were used as negative controls. Transformants containing the plasmids pGBKT7-p53 (murine p53 fused to the GAL4 DNA-binding domain) and PGADT7-T were used as positive controls (C+).
DENV2 NS3-interacting partners identified by the yeast two-hybrid screen.
| Abbreviation | Gene Name | NCBI ID | Numbers of clones | Biological Process |
|---|---|---|---|---|
| A2M | alpha-2-macroglobulin | NM_000014.4 | 1 | Serine Protease Inhibitor |
| ALDOB | aldolase B, fructose-biphosphate | NM_000035.3 | 1 | Glycolytic Process |
| AP2A2 | adaptor-related protein complex 2, alpha 2 subunit | NM_012305.3 | 1 | Protein Transporter Activity |
| APEH | acylaminoacyl-peptide hydrolase | NM_001640.3 | 1 | Serine-type Endopeptidase Activity |
| APOH | apolipoprotein H (beta-2-glycoprotein I) | NM_000042.2 | 11 | Triglyceride Metabolic Process |
| ATIC | 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase | NM_004044.6 | 1 | Purine Biosynthesis |
| AZGP1 | alpha-2-glycoprotein 1, zinc-binding | NM_001185.3 | 4 | Antigen Binding |
| CFB | complement factor B | NM_001710.5 | 1 | Regulation of Complement Activation |
| CYP2C8 | cytochrome P450, family 2, subfamily C, polypeptide 8 | NM_000770.3 | 1 | arachidonic acid metabolic process omega-hydroxylase P450 pathway oxidation-reduction process |
| EIF6 | eukaryotic translation initiation factor 6 | NM_002212.3 | 1 | translation initiation factor activity |
| FBLN2 | fibulin 2 | NM_001998.2 | 1 | extracellular matrix organization |
| FGB | fibrinogen beta chain | NM_005141.4 | 2 | blood coagulation platelet activation |
| GAPDH | glyceraldehyde-3-phosphate dehydrogenase | NM_002046.5 | 1 | Glycolytic Process |
| GBAS | glioblastoma amplified sequence | NM_001483.2 | 1 | ATP biosynthetic process oxidative phosphorylation |
| GUK1 | guanylate kinase 1 | NM_001159390.1 | 1 | ATP metabolic process |
| HPR | haptoglobin-related protein | NM_020995.3 | 5 | receptor-mediated endocytosis hemoglobin binding |
| MRPL24 | mitochondrial ribosomal protein L24 | NM_024540.3 | 1 | structural constituent of ribosome |
| MT2A | metallothionein-2A | NM_005953.3 | 1 | cellular copper ion homeostasis |
| MT-CO2 | cytochrome c oxidase subunit II | 1 | respiratory electron transport chain | |
| NFYC | nuclear transcription factor Y, gamma | NM_001142588.1 | 1 | transcription coactivator activity |
| NIT2 | nitrilase family, member 2 | NM_020202.4 | 1 | asparagine, glutamine and oxaloacetate metabolic process |
| PHB | prohibitin | NM_002634.3 | 1 | histone deacetylase binding negative regulation of cell growth negative regulation of transcription, |
| SCRN2 | secernin 2 | NM_138355.3 | 2 | dipeptidase activity |
| SERPINA3 | serpin peptidase inhibitor, clade A member 3 | NM_001085.4 | 1 | serine-type endopeptidase inhibitor activity regulation of lipid metabolic process |
| SERPINC1 | serpin peptidase inhibitor, clade C (antithrombin), member 1 | NM_000488.3 | 1 | serine-type endopeptidase inhibitor activity |
| SIGIRR | single immunoglobulin and toll-interleukin 1 receptor (TIR) domain | NM_021805.2 | 1 | negative regulation of cytokine-mediated signaling pathway negative regulation of lipopolysaccharide-mediated signaling pathway |
| TF | transferrin | NM_001063.3 | 1 | blood coagulation |
| TUFM | Tu translation elongation factor, mitochondrial | NM_003321.4 | 1 | mitochondrial translation |
Figure 2The human GAPDH protein directly binds the full-length DENV2 NS3 protein and its helicase and protease domains. A binding ELISA was performed using microtiter plates coated with 50 μg/mL each of the purified full-length NS3 protein (A), NS3 helicase domain (C) or NS3 protease domain (E), followed by incubation with increasing concentrations of human GAPDH and detection with an anti-GAPDH polyclonal antibody. A two-way ANOVA followed by Bonferroni post-test was used to calculate statistical significance between the control and NS3-containing curves. The bar graphs represent the area under the curve (AUC) for each NS3 construct compared to its corresponding negative control (BSA). The error bars indicate the standard deviation from three independent experiments, and the p values show significant differences between NS3 constructs and BSA curves, calculated by unpaired Student’s t test. SPR sensorgrams reflect the binding of the recombinant full-length NS3 protein (B) and the helicase (D) and protease (F) domains to the immobilized GAPDH protein. The amount of full-length NS3 and its domains that associated with GAPDH was measured in response units (RU). The global equilibrium dissociation constant values (KD) were calculated.
Figure 3The interaction between GAPDH and recombinant full-length NS3 or the helicase domain decreases GAPDH activity. Enzymatic activity was measured in a buffer containing 50 mM Tris-HCl, pH 7.4, 2 mM MgCl2, 1 mM ATP, 1 mM EDTA, 0.25 mM β-NADH, 13 units/mL phosphoglycerate kinase (PGK) and 1 µM human GAPDH. The reaction was incubated with increasing concentrations (1 to 3 µM) of the full-length NS3 protein (A,B), as well as the helicase (C,D) and NS3 protease (E,F) domains. The negative control was performed with 3 µM BSA. The reactions were triggered by the addition of 5 mM 3-phosphoglycerate. GAPDH activity was expressed as the decrease in the relative fluorescence intensity (F/F0) of NADH after its conversion to NAD+. The relative fluorescence intensity data were then converted to percentages using a representative time point from each reaction (10 min) to better show the effects on GAPDH activity as a function of incubation with different amounts of the NS3 proteins. The data were obtained in three independent experiments, and the bars indicate the standard errors. Statistically significant differences were analyzed using a two-tailed, unpaired Student’s t-test. *p < 0.05, **p < 0.01, and ***p < 0.001.
Figure 4Human GAPDH increases NS3 ATPase activity. The human GAPDH protein (from 0.25 μM to 4 μM) was added to 40-µL reactions containing 40 mM MES-Tris-HCl, pH 7.5, 5 mM DTT, 5 mM MgCl2, 100 mM KCl and 0.3 µM recombinant full-length NS3 protein (A) or its helicase domain (B). The reactions were triggered with 1 mM ATP. The formation of free Pi resulted in a blue-colored reaction, which was measured at 660 nm after the addition of ammonium molybdate and a reducing agent. The percentage of ATPase activity was calculated relative to the reaction without the GAPDH protein. The negative control was performed with 4 µM BSA. The error bars indicate the standard deviations from three independent experiments, and asterisks indicate significant differences from the control using two-way ANOVA and the Bonferroni post-test. *p < 0.05, **p < 0.01, and ***p < 0.001.
Figure 5Representation of the DENV2 NS3-GAPDH complex by molecular docking. The 3D models of full-length DENV2 NS3 (green and red) and its separated protease (green) and helicase (red) domains were used as receptors. Human GAPDH monomer (blue) was used as the ligand. The amino acid residues found at protein interfaces are shown in spheres. The GAPDH catalytic residues, cysteine 152 (Cys152) and histidine 179 (His179), are shown in orange spheres. Human GAPDH binds full-length DENV2 NS3 (A) and its protease domain (C) using the same interaction interface. The binding site changes when GAPDH interacts with the NS3 helicase domain (B). Structures (D–F) correspond to (A–C) respectively, without the representation of the DENV2 NS3 structures to highlight the amino acid residues (blue spheres) of the GAPDH protein that are at the contact interface. The structure represented in G highlights the amino acid residues (blue spheres) of the GAPDH protein that are at the contact interface with DENV2 NS1, as described previously[39] (the NS1 structure was not represented for better visualization). (A–C) are displayed in the same orientation among each other. (D–G) Are displayed in the same orientation among each other. Docking structures were generated by the web-based server Cluspro 2.0 and displayed with PyMOL.
Score values for the full-length DENV2 NS3, the protease and helicase domains and human GAPDH docking.
| System | Cluster number | Number of representatives | Balanced score | |
|---|---|---|---|---|
| full-length NS3 + GAPDH | 1 | 51 | Center | −881.6 |
| Lowest energy | −881.6 | |||
| NS3 protease + GAPDH | 0 | 86 | Center | −807.0 |
| Lowest energy | −807.0 | |||
| NS3 helicase + GAPDH | 0 | 63 | Center | −802.0 |
Figure 6DENV2 NS3 interacts with the GAPDH protein in DENV2-infected Huh7.5.1 cells and in NS3-transfected BHK-21 cells. (A) Extracts from mock- or DENV2-infected Huh7.5.1 cells were coimmunoprecipitated with an anti-GAPDH rabbit polyclonal antibody covalently coupled to an amino-linked agarose resin. Elution was carried out using the elution buffer provided in the co-IP kit (Pierce). The input (IN), flow-through (FT) and eluted (EL) fractions were analyzed by western blotting using mouse anti-NS3 polyclonal and rabbit anti-GAPDH polyclonal antibodies. Gel bands of 37 and 70 kDa, which corresponded to the GAPDH and NS3 proteins, respectively, were observed in the elution fractions of the coimmunoprecipitation. (B) Extracts from DENV2-infected Huh7.5.1 cells were incubated with control IgG coupled to an amino-linked agarose resin. (C) Extracts from pcDNA3.1 or pcDNA3.1-NS3-transfected BHK-21 cells were coimmunoprecipitated with an anti-NS3 rabbit polyclonal antibody covalently coupled to an amino-linked agarose resin. The following steps were the same as described in (A). The purified human GAPDH protein (Abcam) and full-length DENV2 NS3 were used as positive controls (C+) as indicated in the Figure. The results presented are representative of three independent experiments. The blots were cropped from the same western blotting membrane. Full-length blots/gels are presented in Supplementary Data.
Figure 7Human GAPDH relocalizes to ER membranes and colocalizes with NS3 in DENV2-infected Huh7.5.1 cells and in NS3-transfected BHK-21 cells. (A) Huh7.5.1 cells were mock- or DENV2-infected at an MOI of 2, fixed 48 h post-infection and subjected to double-immunofluorescence staining with polyclonal anti-GAPDH (red stained), polyclonal anti-NS3 (green stained) or monoclonal anti-calreticulin (red stained) antibodies. GAPDH shows diffuse localization in mock-infected cells. The distribution of GAPDH in DENV2-infected cells shows intense perinuclear signals that coincide with NS3 localization, as revealed by the merged images. The colocalization of NS3 with calreticulin, an ER marker, was observed in DENV2-infected cells. Nuclei were counterstained with DAPI (blue). (B) BHK-21 cells were transfected with pcDNA3.1 (negative control) or pcDNA3.1-NS3, fixed 48 h post-transfection and subjected to double-immunofluorescence staining with polyclonal anti-GAPDH (red stained), polyclonal anti-NS3 (green stained). Nuclei were counterstained with DAPI (blue).
Figure 8DENV3 generates hepatic steatosis, and the DENV3 NS3 protein colocalizes with GAPDH in hepatic tissue from a fatal dengue case. Liver sections from a healthy donor (A–B) or a DENV3-infected patient (C–D) were stained with hematoxylin and eosin for histological analysis or incubated with purified mouse polyclonal anti-NS3 helicase (green fluorescent) and rabbit polyclonal anti-GAPDH antibodies (red fluorescent) (E–F). Hematoxylin-and-eosin-stained liver sections from the non-dengue case show a normal appearance (A–B), whereas liver sections from the infected fatal case presented hepatic injuries in the form of microsteatosis (St) (C) and Kupffer cell and lymphocyte infiltrates (D). The NS3 protein was not detected in control tissue (E), but GAPDH and DENV3 NS3 colocalized in infected hepatic tissue (F), as observed in the merged images of hepatocytes and Kupffer cells. Hepatocytes (H); Sinusoidal Capillary (S); Biliary Duct (BD), Portal Space (PS); Steatosis (St); Kupffer cells (KC); and Lymphocytes (Ly).
Figure 9DENV2 NS3 protein decreases the intracellular GAPDH glycolytic activity in DENV2-infected and NS3-transfected cells. Intracellular GAPDH activity was monitored in a coupled reaction with TPI, in which dihydroxyacetone phosphate was converted into glyceraldehyde-3-phosphate, the GAPDH substrate. Kinetics of NADH were monitored by the increase in absorbance at 340 nm every 1 min for 90 min, using 50 µg of the cell extract of DENV2-infected (A) or NS3-transfected BHK-21 cells (B) as the source of the enzyme. The conversion of absorbance units into NADH production was determined by molar absorptivity of NADH (6.22 mM−1 cm−1). The concentration of NADH was converted into GAPDH activity, considering that one unit of enzyme activity corresponds to the reduction of 1 µM of β-NAD/min (C).